<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737202</url>
  </required_header>
  <id_info>
    <org_study_id>SLAM 7602</org_study_id>
    <secondary_id>4UH3TR000961-02</secondary_id>
    <nct_id>NCT02737202</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis</brief_title>
  <acronym>SLAM-2</acronym>
  <official_title>Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine if there is a potential benefit of saracatinib in LAM
      subjects. Based on the information of this trial, additional clinical development trials will
      be needed. The study will also test the tolerability of 125 mg of saracatinib given once
      daily over a 9 month period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in
      tuberous sclerosis complex 1 (TSC1) or TSC2 tumor suppressor genes. TSC is characterized by
      tumors in a wide range of tissues, seizures, mental retardation, autism, and organ failure.
      Lymphangioleiomyomatosis (LAM), the major pulmonary manifestation in women with TSC, is a
      progressive lung disease characterized by infiltration of atypical smooth muscle like cells
      (TSC-/- LAM cells) and formation of parenchymal cysts. Sporadic LAM can develop in women who
      do not meet the criteria for the diagnosis of TSC, owing to somatic mutations in the TSC2
      gene.

      The long term goal of this research is to devise novel therapeutic strategies for patients
      with LAM. The observed behavior of LAM cells with respect to their infiltrative growth
      pattern, metastatic potential, and altered cell differentiation is reminiscent of cells
      undergoing epithelial-mesenchymal transition (EMT). Src kinases are key regulators of
      cellular proliferation, motility, invasiveness and EMT. Recent results have shown that
      autophagy promotes degradation of active Src. Thereby, decreased autophagy due to mTOR
      activation known to occur in LAM cells, may play a significant role in accumulation of active
      Src in these cells. Src suppresses transcription of E-cadherin by upregulating its
      transcriptional repressors. The preliminary data reveal an increase in active Src in lung
      tissues of patients with LAM as well as in cultured TSC2-/- cells. Further, in TSC2-/- cells,
      E-cadherin is considerably reduced and does not localize to the plasma membrane, as it does
      in wild-type cells.

      The focus of this study is to examine if Src inhibition represents a potential therapeutic
      strategy in LAM. It is proposed that Src activation in TSC2-/- cells results in the reduction
      of E-cadherin, loss of cell-cell adhesion and elevation of oncogenic and metastatic potential
      of these cells. The increased Src activity in TSC2-/- cells is likely caused by inhibition of
      autophagy associated with hyper-activation of mTOR. Therefore, the use of Src inhibitors may
      lead to a reduction in tumor growth and prevent dissemination of TSC2-/- cells. In this
      study, the investigators will evaluate the safety and efficacy of Src inhibition in subjects
      with LAM.

      A number of inhibitors of Src are now in clinical trials in patients with a range of
      different tumors. Dasatinib, an oral adenosine triphosphate (ATP)-competitive Src inhibitor,
      is now approved for clinical use in patients with chronic myeloid leukemia or acute
      lymphoblastic leukemia. However, dasatinib has wider 'off target' inhibitory activity than
      saracatinib including potent activity against Abl, ephrin receptor kinases, platelet-derived
      growth factor receptor and c-KIT (type of receptor tyrosine kinase and a type of tumor
      marker. Also called CD117 and stem cell factor receptor.) In contrast, saracatinib has a
      &gt;10-fold preference for Src over Abl kinases and has very little activity against other
      tyrosine and serine/threonine kinases. Saracatinib has been already characterized in multiple
      clinical trials in terms of safety and pharmacokinetics.

      The investigators have conducted a Phase1b study to test the safety of various doses of
      Saracatinib in LAM subjects. The purpose of the Phase1b trial was to determine the optimal
      dose in terms of safety and tolerability in LAM population. Three escalating doses of
      saracatinib; 50, 125 and 175 mg were studied. Saracatinib was given orally once a day.
      Overall, subjects tolerated Saracatinib well. The investigators chose the dose of 125 mg to
      conduct further testing of both safety and efficacy in this Phase 2a trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiomyolipoma measured volumetrically on MRI</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Cyst size measured on chest CT</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF-D serum levels</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pulmonary Function Testing</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Pulmonary Lymphangioleiomyomatosis</condition>
  <arm_group>
    <arm_group_label>Saracatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saracatinib</intervention_name>
    <description>Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.</description>
    <arm_group_label>Saracatinib</arm_group_label>
    <other_name>AZD0530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients. It should be noted that LAM occurs almost exclusively in women.

          -  18 to 65 years of age.

          -  All patients must have a diagnosis of LAM as defined by compatible cystic changes on
             chest computed tomography (CT) and one of the following:

          -  Open lung, transbronchial or thoracic needle biopsy consistent with LAM

          -  Open or needle abdominal biopsy findings consistent with LAM

          -  Clinical findings of tuberous scleroma complex (TSC), renal angiomyolipoma, cystic
             abdominal lymphangiomas, or history of chylous effusion in the chest or abdomen

          -  Serum vascular endothelial growth factor D (VEGF-D) &gt; 800 pg/ml

          -  Subjects must have had a recent reduction in forced expiratory volume at 1-second
             (FEV1) of &gt; 50ml/year, as shown by at least two pulmonary function testing (PFT)
             measured at least 6 months apart in the last 24 months prior to enrolling study.

        Exclusion Criteria:

          -  Current infection.

          -  Major surgery within the past 2 months

          -  Advanced hematologic, renal, hepatic, non-LAM lung disease or metabolic diseases; or
             BMI of &gt;35

          -  The use of another investigational drug within 30 days

          -  The use of mTOR (mammalian target of rapamycin) inhibitors within 30 days

          -  Previous lung transplantation.

          -  Inability to attend scheduled clinic visits

          -  Inability to give informed consent

          -  Inability to perform pulmonary function testing

          -  History of malignancy in the past two years, other than squamous or basal cell skin
             cancer or status post successful excision or treatment.

          -  Nursing mothers

          -  Current or planned pregnancy.

          -  Not using adequate contraception (in woman of childbearing potential).

          -  Significant clinical change in health in the past 30 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Eissa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola A Hanania, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben Taub Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis X McCormack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Dilling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Ruoss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Moss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory of Translational Research - NHLBI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa A Brock</last_name>
    <phone>713-873-8772</phone>
    <email>mbrock@bcm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caryn o Pope</last_name>
    <email>carynopope@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Jacobs, RN MS</last_name>
      <phone>650-725-8083</phone>
      <email>ssjpulm@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Ruoss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>90153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kirwan, RN</last_name>
      <phone>708-216-2057</phone>
      <email>ekirwan@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Dilling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laboratory of Translational Research NHLBI</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Haughey, RN</last_name>
      <phone>301-496-3632</phone>
      <email>mhaughey@nhlbi.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Joel Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Roads</last_name>
      <phone>513-558-2148</phone>
      <email>roadst@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Frank X McCormack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Ben Taub General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caryn O Pope</last_name>
      <phone>713-873-2471</phone>
      <email>cpope@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Nicola A Hanania, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Young J, Povey S. The genetic basis of tuberous sclerosis. Mol Med Today. 1998 Jul;4(7):313-9. Review.</citation>
    <PMID>9743993</PMID>
  </reference>
  <reference>
    <citation>Kobayashi T, Minowa O, Sugitani Y, Takai S, Mitani H, Kobayashi E, Noda T, Hino O. A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8762-7. Epub 2001 Jul 3.</citation>
    <PMID>11438694</PMID>
  </reference>
  <reference>
    <citation>Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet. 2003 Jan;67(Pt 1):87-96. Review.</citation>
    <PMID>12556239</PMID>
  </reference>
  <reference>
    <citation>European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993 Dec 31;75(7):1305-15.</citation>
    <PMID>8269512</PMID>
  </reference>
  <reference>
    <citation>van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Sampson JR, Reeve MP, Richardson P, Wilmer F, Munro C, Hawkins TL, Sepp T, Ali JB, Ward S, Green AJ, Yates JR, Kwiatkowska J, Henske EP, Short MP, Haines JH, Jozwiak S, Kwiatkowski DJ. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997 Aug 8;277(5327):805-8.</citation>
    <PMID>9242607</PMID>
  </reference>
  <reference>
    <citation>Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc. 2000 Jun;75(6):591-4.</citation>
    <PMID>10852420</PMID>
  </reference>
  <reference>
    <citation>Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001 Aug 15;164(4):661-8.</citation>
    <PMID>11520734</PMID>
  </reference>
  <reference>
    <citation>Astrinidis A, Khare L, Carsillo T, Smolarek T, Au KS, Northrup H, Henske EP. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet. 2000 Jan;37(1):55-7.</citation>
    <PMID>10633137</PMID>
  </reference>
  <reference>
    <citation>Illouz F, Braun D, Briet C, Schweizer U, Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014 Sep;171(3):R91-9. doi: 10.1530/EJE-14-0198. Epub 2014 May 15. Review.</citation>
    <PMID>24833135</PMID>
  </reference>
  <reference>
    <citation>Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. Br J Haematol. 2014 Feb;164(4):608-10. doi: 10.1111/bjh.12648. Epub 2013 Nov 13.</citation>
    <PMID>24219400</PMID>
  </reference>
  <reference>
    <citation>Tyryshkin A, Bhattacharya A, Eissa NT. SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis. Cancer Res. 2014 Apr 1;74(7):1996-2005. doi: 10.1158/0008-5472.CAN-13-1256.</citation>
    <PMID>24691995</PMID>
  </reference>
  <reference>
    <citation>Goncharova EA, Goncharov DA, Damera G, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis. Mol Pharmacol. 2009 Oct;76(4):766-77. doi: 10.1124/mol.109.057042. Epub 2009 Jul 13.</citation>
    <PMID>19596836</PMID>
  </reference>
  <reference>
    <citation>Siemann DW, Dong M, Pampo C, Shi W. Src-signaling interference impairs the dissemination of blood-borne tumor cells. Cell Tissue Res. 2012 Aug;349(2):541-50. doi: 10.1007/s00441-012-1415-7. Epub 2012 Apr 18.</citation>
    <PMID>22526632</PMID>
  </reference>
  <reference>
    <citation>Dong M, Rice L, Lepler S, Pampo C, Siemann DW. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Res. 2010 Nov;30(11):4405-13.</citation>
    <PMID>21115886</PMID>
  </reference>
  <reference>
    <citation>Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Plé PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 2009 Jun;3(3):248-61. doi: 10.1016/j.molonc.2009.01.002. Epub 2009 Feb 7.</citation>
    <PMID>19393585</PMID>
  </reference>
  <reference>
    <citation>Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, Green TP, Elvin P, Womack C, Clack G, Dixon JM. Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Res Treat. 2009 Mar;114(2):211-21. doi: 10.1007/s10549-008-9997-1. Epub 2008 Apr 14.</citation>
    <PMID>18409068</PMID>
  </reference>
  <reference>
    <citation>Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085-90.</citation>
    <PMID>10823953</PMID>
  </reference>
  <reference>
    <citation>Dalton RN, Chetty R, Stuart M, Iacona RB, Swaisland A. Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects. Anticancer Res. 2010 Jul;30(7):2935-42.</citation>
    <PMID>20683035</PMID>
  </reference>
  <reference>
    <citation>Leeming DJ, Sand JM, Nielsen MJ, Genovese F, Martinez FJ, Hogaboam CM, Han MK, Klickstein LB, Karsdal MA. Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights. 2012;7:119-26. Epub 2012 Sep 13.</citation>
    <PMID>23012495</PMID>
  </reference>
  <reference>
    <citation>Taveira-Dasilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Bone mineral density in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2005 Jan 1;171(1):61-7. Epub 2004 Oct 1.</citation>
    <PMID>15466255</PMID>
  </reference>
  <reference>
    <citation>Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. Am J Respir Crit Care Med. 2003 May 1;167(9):1287.</citation>
    <PMID>12714344</PMID>
  </reference>
  <reference>
    <citation>Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003 Sep;64(3):1035-45.</citation>
    <PMID>12911554</PMID>
  </reference>
  <reference>
    <citation>Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008 Jan 10;358(2):199-200. doi: 10.1056/NEJMc0707517.</citation>
    <PMID>18184970</PMID>
  </reference>
  <reference>
    <citation>Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006;4(3):143-52.</citation>
    <PMID>17034294</PMID>
  </reference>
  <reference>
    <citation>Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001 Feb;7(2):186-91.</citation>
    <PMID>11175849</PMID>
  </reference>
  <reference>
    <citation>Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53.</citation>
    <PMID>9435229</PMID>
  </reference>
  <reference>
    <citation>Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A, Otterbein L, Plé PA, Warin N, Costello G. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006 Nov 2;49(22):6465-88.</citation>
    <PMID>17064066</PMID>
  </reference>
  <reference>
    <citation>Recchia I, Rucci N, Funari A, Migliaccio S, Taranta A, Longo M, Kneissel M, Susa M, Fabbro D, Teti A. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone. 2004 Jan;34(1):65-79.</citation>
    <PMID>14751564</PMID>
  </reference>
  <reference>
    <citation>Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD, Eastell R. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res. 2010 Mar;25(3):463-71. doi: 10.1359/jbmr.090830. Erratum in: J Bone Miner Res. 2012 Jun;27(6):1435.</citation>
    <PMID>19775203</PMID>
  </reference>
  <reference>
    <citation>de Vries TJ, Mullender MG, van Duin MA, Semeins CM, James N, Green TP, Everts V, Klein-Nulend J. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res. 2009 Apr;7(4):476-88. doi: 10.1158/1541-7786.MCR-08-0219.</citation>
    <PMID>19372577</PMID>
  </reference>
  <reference>
    <citation>Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.</citation>
    <PMID>20805299</PMID>
  </reference>
  <reference>
    <citation>Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2635-40. doi: 10.1073/pnas.0810790106. Epub 2009 Feb 6.</citation>
    <PMID>19202070</PMID>
  </reference>
  <reference>
    <citation>Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.</citation>
    <PMID>23035046</PMID>
  </reference>
  <reference>
    <citation>Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control. 2006 Oct;13(4):276-85. Review.</citation>
    <PMID>17075565</PMID>
  </reference>
  <reference>
    <citation>Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist. 2011;16(5):566-78. doi: 10.1634/theoncologist.2010-0408. Epub 2011 Apr 26. Review.</citation>
    <PMID>21521831</PMID>
  </reference>
  <reference>
    <citation>McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.</citation>
    <PMID>21410393</PMID>
  </reference>
  <reference>
    <citation>Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M, Wu JJ, Finkel T, Kwiatkowski DJ, Yu JJ, Henske EP. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12455-60. doi: 10.1073/pnas.1104361108. Epub 2011 Jul 11.</citation>
    <PMID>21746920</PMID>
  </reference>
  <reference>
    <citation>Tyryshkin A, Gorgun FM, Abdel Fattah E, Mazumdar T, Pandit L, Zeng S, Eissa NT. Src kinase-mediated phosphorylation stabilizes inducible nitric-oxide synthase in normal cells and cancer cells. J Biol Chem. 2010 Jan 1;285(1):784-92. doi: 10.1074/jbc.M109.055038. Epub 2009 Oct 29.</citation>
    <PMID>19875457</PMID>
  </reference>
  <reference>
    <citation>Marin TM, Clemente CF, Santos AM, Picardi PK, Pascoal VD, Lopes-Cendes I, Saad MJ, Franchini KG. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways. Circ Res. 2008 Oct 10;103(8):813-24. doi: 10.1161/CIRCRESAHA.108.179754. Epub 2008 Aug 28.</citation>
    <PMID>18757826</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Tony Eissa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>LAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saracatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

